Matinas Biopharma reports FY16 results; shares up 8% premarket

|About: Matinas Biopharma Holdings... (MTNB)|By:, SA News Editor

Matinas Biopharma Holdings (MTNB +0.7%) FY16 results: Revenues: $0; R&D Expense: $3.9M (-26.4%); SG&A: $4.3M (-10.4%); Operating Loss: ($8.3M) (+16.2%); Net Loss: ($7.6M) (+16.5%); Loss Per Share: ($0.21) (-16.7%); Quick Assets: $4.1M (+28.1%).

No guidance given.

Shares are up 8.3% premarket.

See important disclosures.